The term non-alcoholic steatohepatitis (NASH) describes liver disease histologically similar to alcoholic liver disease occurring in patients without any history of excessive alcohol consumption [1, 2] . Two main histological criteria are necessary for the diagnosis of NASH: fatty degeneration and inflammation or fibrosis. The latter criteria distinguishes NASH from simple steatosis which has a non-progressive course [3] . In western countries, NASH is a major cause of increased liver enzymes, next to alcohol consumption and hepatitis C [2] . It is frequently associated with obesity (40 %), Type II diabetes (20 %) and hyperlipidaemia (20 %) We therefore assessed the association between a functional polymorphism in the promoter region of MTP gene (±493 G/T) and the biological features of steatohepatitis in Type II diabetic patients. Methods. We studied 271 patients with Type II diabetes. Determination of ±493 G/T polymorphism was made by PCR-RFLP. Increased liver enzymes were used as surrogates of liver steatosis and alanine aminotransferase concentration was the outcome variable for the multivariate analysis. Liver ultrasonography was available for a subgroup of patients with newly diagnosed diabetes.
pothesised that occurrence of NASH requires a twohit process. The first one leads to hepatic steatosis and the second is required to turn steatosis into NASH [7] . Several overlapping causal factors emerged as candidates for NASH: (1) metabolic disorders, i. e. insulin resistance, abnormal fatty acid metabolism and intrahepatic accumulation of triglycerides [1, 8, 9] , (2) increased oxydative stress [8, 10] and (3) increased production of cytokines [8, 11] .
An increased concentration of triglycerides in hepatocytes is the result of increased synthesis or decreased secretion of VLDL. The microsomal triglyceride transfer protein (MTP) is necessary for assembly and secretion of VLDL from hepatocytes [12] . It has a key role in lipoprotein assembly, by transferring lipid (especially triglycerides) to nascent apoB. Liver steatosis is a characteristic of abetalipoproteinaemia, a rare autosomal recessive disease caused by mutations in the coding region of MTP gene, resulting in a very low total cholesterol, undetectable plasma apolipoprotein B and fat malabsorption [12, 13] .
Only a subgroup of subjects with Type II diabetes has NASH. It is more commonly encountered in those with the most severe insulin resistance syndrome. With similar clinical features and glycaemic control only a fraction of non-drinker Type II diabetic patients develop NASH, hence the hypothesis of a genetic susceptibility. A common functional polymorphism has been recently described in the promoter region of the MTP gene (±493 G/T) [14] . The G allele is associated with decreased gene transcription compared with the T allele. Therefore the MTP gene is a good candidate for genetic susceptibility to NASH. The aim of this study was to investigate the relation between this functional MTP gene polymorphism and the biological surrogates of liver steatosis in Type II diabetic patients.
Subjects and methods
Subjects and blood samples. The patients were 271 consecutive Caucasian Type II diabetic patients (35±73 years old, 141 men and 130 women) who had at least one additional cardiovascular risk factor and participated in our local prospective study of Type II diabetes (DIACOR study), which aimed to test the predictive value of carotid intima-media thickness for cardiovascular events. Exclusion criteria were: ketonuria, fasting glycaemia above 15 mmol/l, insulintherapy, concomitant illness (hepatic or renal insufficiency, neoplasia), history of severe hypertriglyceridaemia ( > 10 g/l), and heavy alcohol consumption ( > 40 g/day). All patients were questioned about their diet by a registered dietetician. Of the patients 48 were receiving hypolipidemic drug therapy and 225 being treated with oral antidiabetic agents. All had given written informed consent before DNA analysis and this study had the approval of our local ethics committee. Blood samples were drawn, after an overnight fast, into tubes containing EDTA and plasma was immediately separated by low-speed centrifugation.
±493 G/T MTP gene polymorphism. The polymorphism was detected by PCR-RFLP using a two-step nested PCR according to the method described by Karpe [14] . Briefly, the first step of the PCR amplified a 838 bp fragment with the following two primers: 5'-CCCTCTTAATCTCTTTCCTAGAA (MTP-1) and 5'-AAGAATCATATTGACCAGCAATC (MTP-2). The second step of the PCR was then done using a 5' primer including a mutation to give rise to an Hph1 cutting site for the G allele. The mutated primer was 5'-GGATTTAAATTTAAA-CTGTTAATTCATATCAC and the other primer 5'-AG-TTTCACACATAAGGACAATCATCTA. This second step of the PCR amplified a 109 bp fragment. The PCR products (20 ml) were incubated with Hph1 (1 UI) for 2 h at 37 C. Restriction fragment length polymorphism (RFLP) was analysed by high resolution using 3 % agarose gel as an electrophoretic media stained with ethidium bromide. The T allele gave rise to a full-length fragment of 109 bp and G allele to two fragments of 89 and 20 bp. Samples with different PCR-RFLP patterns (GG and TT homozygotes and GT heterozygotes) were directly sequenced (Sanger method) to validate the PCR-RFLP method [15] .
Biological variables. Liver tests included alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), and gamma-glutamyl transferase (gGT). Ferritinaemia and transferrin saturation were also measured in a subgroup of 107 patients with newly diagnosed Type II diabetes. None of them had an increase in transferrin coefficient above 0.50. Hepatitis B and C serology was done when serum ALAT, ASATor gGTwas above the upper normal range. Subjects with positive hepatitis serology were excluded. Haemoglobin A 1 c (HbA 1 c ) was evaluated by HPLC. Total cholesterol and triglycerides were measured using commercial kits (BiomØrieux, Lyon, France). We obtained HDL-containing fractions after precipitation of apolipoprotein B (apoB)-containing lipoproteins by heparin/MnCl2 [16] .
Liver ultrasonography. Ultrasonography was systematically carried out in the subgroup of newly diagnosed diabetic patients (107/271) after an overnight fast. The operator was blind for liver enzymatic status. Liver hyperechoic structure was reported, specifying homogeneity or heterogenity of tissue. Echographic criteria for steatosis were an hyperechoic structure with a posterior absorption and attenuation of the diaphragmatic dome.
Statistical analysis. Categorical variables were assessed by the chi-squared test. Univariate regression analysis (correlation coefficient of Spearman) was used to analyse the relation between continuous variables. Comparison of means between genetic groups was tested by one-way analysis of variance. The association between MTP genotype and ALAT concentration was assessed by a multivariate analysis using a general linear logistic regression model, taking other clinical and biological characteristics into account [17] . The outcome factor, i. e. ALAT concentration was assessed as a dichotomous variable (cut-off: 45 U/l: upper concentration of the normal range in our enzymatic ALAT assay). The explanatory variables were: the MTP gene polymorphism, the clinical (sex, age, BMI and systolic blood pressure) and the biological (HbA 1 c , HDL-c and triglycerides) characteristics of the patients. The effect of the MTP gene polymorphism was assessed by a dichotomous variable: GG homozygous compared with GT heterozygous and TT homozygous. The continuous clinical variables (age, BMI, systolic blood pressure) and the biological variables were standardised. The chi-squared tests for the parameter values were Wald tests. Results were presented with a level of significance considered at p < 0.05. Analysis was done with Statistical Analysis Sofware (SAS Institute, Cary, N. C., USA).
Results
The analysis of RFLP products showed similar allele frequencies for ±493 G/T MTP gene polymorphism in this Type II diabetic cohort as previously described in healthy Caucasian subjects: 25 % and 75 % for T and G alleles, respectively [14] . Haplotype frequencies were also the same as those published previously (GG: 55.7 %, GT: 37.6 %, TT: 6.7 %) and were in the Hardy-Weinberg equilibrium [14] . There were no differences between genetic groups in sex distribution, age, alcohol consumption, BMI, systolic blood pressure, glycaemic control or lipid variables (Table 1) . A similar proportion of subjects treated with oral antidiabetic agents was observed between genetic groups (84 %, 84 %, 78 %, for GG, GT and TT groups, respectively, p = 0.77). The proportion of subjects with increased ALAT or gGT was similar whether or not the patients were receiving lipid lowering therapy (p = 0.59 and p = 0.51, respectively) moreover the percentage of patients receiving lipid lowering therapy was higher in GT than GG group (33 % and 18 %, respectively).
By contrast, mean concentrations of ALAT and gGT were higher in GG than in GT and TT subgroups (Table 2) but ASAT only displayed a trend towards an increased mean concentration in GG patients. Additionally, the GG subgroup included a higher proportion of patients with increased enzyme concentrations or with ultrasonographic steatosis criteria (Table 3). The proportion of patients with increased ALAT and gGT was not significantly different between GT and TT subgroups.
Univariate regression analysis showed that ALAT, gGT, ASAT, and ferritinaemia were all statistically significantly interrelated. We chose ALAT to reflect liver enzyme alterations because it is considered to be the best indirect biological index of NASH [2, 18] . Patients with increased ALAT were younger than those with normal values (52 8 vs 55 8 years old, p = 0.01). The proportion of subjects with increased ALAT was higher among patients presenting ultrasonographic steatosis criteria (40 % vs 6 %, p = 0.0001). Increased concentrations of ALAT were also significantly more frequent in men, obese subjects and those with low HDL-cholesterol (Table 4) . The frequency of increased ALAT concentrations was not higher in hypertensive subjects (systolic blood pressure > 150 mmHg) or in patients with hypertriglyceridaemia (triglyceride > 2 g/l) or poor glycaemic control (HbA 1 c > 8 %).
After excluding the observations where data were lacking, the analysis by the logistic model concerned 255 patients. Taking various confounding factors into account, ALAT concentration was statistically significantly linked to three variables: MTP genotype, sex and BMI (Table 5) . These results were similar when MTP genotype was entered under the form of three subgroups (GG, GT and TT). Overall, when a subject was homozygous for the G allele of the MTP gene promoter polymorphism the adjusted odds ratio for having an increased concentration of ALAT was 3.5 (95 % confidence limits: 1.6 to 7.9) compared with GT and TT patients. Values are expressed as means ± SD. a p is the degree of significance of the chi-squared test for the variable sex and oneway analysis of variance for the other variables. BP, blood pressure; chol, cholesterol Values are expressed as means ± SD. a p is the degree of significance of the one-way analysis of variance.
b Ferritinaemia was available for a subgroup of 107 patients Table 3 . Per cent of subjects with increased concentration of liver enzymes or with ultrasonographic signs of steatosis according to MTP genotype (44) a p is the degree of significance of the chi-squared test when analyses were done on the basis of two genotype subgroups (GG vs GT + TT). b ALAT: high > 45 U/l; c g GT: high: > 65 U/l for men and > 45 U/l for women.
d Liver ultrasonography was available for the subgroup of patients with newly diagnosed diabetes (n = 107)
Discussion
We report that the ±493 G/T MTP gene polymorphism is associated with a higher proportion of subjects with increased liver enzymes (ALAT and gGT) in the GG subgroup compared with the GT and TT groups. In this study we evaluate the potential effect of a common functional variant of MTP gene on biological surrogates of liver steatosis.
Our data provide only indirect evidence of a link between a MTP gene polymorphism and NASH as liver biopsy specimens were not obtained for ethical reasons. Alanine aminotransferase is, however, commonly used as a surrogate of non-alcoholic liver steatosis and is considered to be a clinically relevant variable [4, 19, 20] . The concentration of ASAT which is more associated with alcohol consumption was increased in the same proportion of patients in the three genetic groups [2, 18] . In the subgroup of patients with an ultrasonographic criteria of steatosis, increased ALAT concentration was more frequently observed and the incidence of GG genotype was higher than in subjects with no ultrasonographic evidence of steatosis. It should be emphasised that the indication of ultrasonography was not based on increased ALAT concentration but newly diagnosed diabetes, lessening recruitment bias. In addition a trend was noted towards a statistically non-significant increase in ferritinaemia in the GG subgroup correlating with the hepatosiderosis syndrome frequently associated with NASH [4, 21, 22] . This converging evidence makes it unlikely that it was by chance that there was a higher proportion of subjects with increased ALAT concentrations in the GG subgroup. Furthermore, multivariate analysis strongly supports an independent contribution of the MTP genotype to increased ALAT concentrations in this Type II diabetic cohort at high risk for NASH.
The MTP gene is a good candidate for the genetic modulation of susceptibility to liver steatosis. A lack of functional MTP protein, such as encountered in abetalipoproteinaemia, is associated with hepatic steatosis [13] . Liver-specific inactivation of the MTP gene has recently been shown to be associated with liver steatosis in the knockout mice [23] . Our data suggest that the G allele of the MTP promoter polymorphism is associated with a higher risk of increased ALAT concentration. The G allele encodes a decrease in MTP gene transcription which would result in a relative decrease of MTP activity and, consequently, of VLDL assembly. In this way, the G allele might contribute to intrahepatocyte triglyceride accumulation resulting in steatosis. The common occurrence of the G allele is compatible with it being a potential causal factor of in NASH which is a frequent disorder in the general population. A moderate reduction in MTP activity as a consequence of this functional polymorphism might, by itself, be insufficient to induce steatosis but could become relevant when there are factors, such as alcohol consumption, insulin resistance or Type II diabetes, present. This is in agreement with a potential recessive effect of the G allele and the absence of an evident allelic dose effect and possibly also with the recessive inheritance of steatosis in abetalipoproteinaemia [13] .
The MTP gene is regulated by factors involved in steatohepatitis, especially alcohol and cytokines. It has been recently reported that ethanol, in addition to the well-known stimulation of hepatic lipogenesis, down-regulated MTP mRNA expression in HepG2 cells by a negative ethanol response element located near the ±493 G/T promoter polymorphism site (±642 to ±142 bp) [24] . It is however unlikely that this mechanism operated in our patients because none of them were heavy drinkers and the level of alcohol consumption was similar in the three genetic groups. Cytokines are thought to be implicated in the two-hit process of NASH, especially in inflammation. A recent study has shown that IL-1 and, to a lesser extent, TNF statistically significantly de- b Odds ratio for a one standard deviation increasing of the variable, except for MTP gene and sex. For a given variable the odds ratio is adjusted for the other variables. BP, blood pressure creased MTP mRNA expression in hamster liver [25] . Increased TNFa expression is thought to be implicated in the development of insulin resistance at the adipocyte level allowing speculation on the effect of a Type II diabetes-related overexpression of TNFa in the facilitation of NASH. Furthermore TNFa has been recently implicated in alcoholinduced liver injury in mice and a polymorphism located in the promoter region of TNFa gene has been associated with susceptibility to alcoholic steatohepatitis [26, 27] .
The MTP gene promoter polymorphism might also have an effect in steatoses other than NASH such as in alcoholic or viral steatosis. The negative effect of alcohol and increased cytokines in viral hepatitis C on MTP gene transcription could be amplified in the presence of the G allele for ±493G/T MTP promoter polymorphism.
Our data suggest a relation between the MTP gene which conditions VLDL assembly and the incidence of steatosis in Type II diabetic patients. They do not preclude an effect of other candidate genes for susceptibility to liver steatosis such as those involved in fatty acid or triglyceride synthesis. Confirmation is needed in other populations at high risk of NASH such as non-diabetic insulin resistant obese subjects.
